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ABBREVIATIONS
AC - Abdominal Circumference
APGAR - Appearance, Pulse, Grimace, Activity, Respiration
AGA - Appropriate for Gestational Age
BPD - Biparietal Diameter
CHT - Chronic Hypertension
FGR - Fetal Growth Restriction
FL - Femoral Length
GA - Gestational Age
GDM - Gestational Diabetes Mellitus
HC - Head Circumference
LGA - Large for Gestational Age
LSCS - Lower segment caesarean section
NICU - Neonatal Intensive Care Unit
SGA - Small for Gestational Age
TCD - Transverse Cerebellar Diameter
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HNF1 beta - Hepatocyte nuclear factor 1beta
HNF4 alpha - Hepatocyte nuclear factor 4 alpha
ADCY5 - Adenylate cyclase type 5
CCNL1 - Cyclin-L1
CPM - Confined Placental Mosaicism
CRH - Corticotrophin Releasing Hormone
SD - Standard Deviation
IUGR - Intrauterine Growth Restriction
PPV - Positive Predictive Value
NPV - Negative Predictive Value
Introduction
INTRODUCTION
The Process of birth is the most dangerous journey an individual
undertakes. A healthy new born is the goal of every expectant mother and
her obstetrician.
It is estimated that the incidence of fetal growth restriction is 3-
10% [1]. Fetal growth restriction is associated with substantial perinatal
morbidity and mortality. Fetal demise, birth asphyxia, meconium
aspiration, neonatal hypoglycemia and hypothermia are all increased in
growth restriction. In addition it has been also found that these growth
restricted infants have increased 1year infant mortality rate [2] and
abnormal neurological development.  The desire to prevent such mal
occurrences during pregnancy has prompted the clinician to develop
various methods of assessing the fetal condition in utero. Ideally the best
investigation must be simple, safe, reproducible, reliable, non- invasive
and accurate and should cause no damage to the mother and fetus.
Prenatal ultrasonography, which fulfills almost all these prerequisites
plays an important role in antepartum fetal surveillance.  An accurate
determination of gestational age, identification of major congenital
anomalies, evaluation of fetal growth and assessment of fetal well being
and maturity are all possible due to the availability of ultrasound.
The assessment of fetal growth is important to the provision of
optimum prenatal care. As the clinical estimation of the fetal growth is
not reliable, prenatal ultrasonography provides an opportunity to more
accurately assess the fetal growth. The most commonly used parameters
to evaluate fetal growth are biparietal diameter (BPD), head
circumference (HC), abdominal circumference (AC) and femur length
(FL). Of all the ultrasound derived biometric parameters, the AC seems
to be the best predictor of fetal growth restriction (FGR).  But all these
parameters can be correlated only if gestational age is accurately known.
But uncertainty of the gestational age occurs frequently and makes the
differentiation between the appropriate for gestational age and the small
for gestational age fetus difficult.
Measurement of   transverse cerebellar diameter (TCD) is an
accurate method of estimating gestational age in cases of uncertain dates
and even in dolicocephaly or brachycephaly where biparietal diameter
could not be used. It has been proposed that TCD is not affected in fetal
growth restriction because of the brain sparing effect(3). Fetal AC is
affected early in the process of growth restriction(4).    Hence, TCD/AC
ratio increases in fetal growth restriction which fairly remains constant
throughout normal pregnancy(5). TCD/AC ratio may convey more precise
information regarding the fetal growth and development than bony
measurements of the fetal head and AC alone.
This study was primarily planned to study the TCD among
pregnant women and to find whether TCD/AC ratio can diagnose   fetal
growth restriction.
Aims
and
Objectives
AIMS AND OBJECTIVES OF THE STUDY
1. To evaluate the validity of TCD/AC ratio in diagnosing fetal
growth restriction.
2. To find out the cut-off value of TCD/AC ratio for diagnosis of fetal
growth restriction.
Review
of
Literature
REVIEW OF LITERATURE
Fetal growth restriction can be defined as a condition where the
fetus fails to achieve its genetic growth potential and consequently is at
risk of increased prenatal morbidity and mortality(6). Incidence of FGR is
approximately 5% in general population. However, the incidence varies
depending on the population under examination and the standard growth
curves used as reference.
Birth weight is usually taken as the sole criterion to assess fetal
growth and consequently fetuses with a birth weight less than the 10th
percentile of those born at the same gestational age, or two standard
deviations below the population mean are considered growth restricted.
However, this definition does not make a distinction among infants who
are constitutionally small, growth-restricted and small, and not small but
growth-restricted relative to their potential. As an example, as many as 70
percent of fetuses who weigh below the 10th percentile for gestational
age are small simply because of constitutional factors such as female sex
or maternal ethnicity, parity, or body mass index; they are not at high risk
of perinatal mortality  or   morbidity (7). Therefore the term FGR refers to
fetuses that are small for gestational age with features of chronic hypoxia
or failure to thrive. Moderate and severe FGR are defined as birth weight
in the 3rd to 10th percentile and less than 3rd percentile, respectively.
Growth percentiles for fetal weight versus gestational age
Normal term infants typically weigh more than 2500 g by 37 weeks
gestation.
1. NORMAL GROWTH
           The process of fetal growth comprises three consecutive and
somewhat overlapping phases. The first phase is the phase of cellular
hyperplasia and encompasses the first 16 weeks of gestation. The second
phase, known as the phase of concomitant hyperplasia and hypertrophy,
occurs between the 16th and 32nd weeks and involves increases in cell size
and number. The third phase, called the phase of hypertrophy, occurs
between 32weeks and term and is characterized by a rapid increase in cell
size.
2.  CLASSIFICATION OF FETAL  GROWTH RESTRICTION
           Campbell and Thoms (1997) described the use of head-to-
abdomen circumference ratio (HC/AC) to differentiate growth restricted
fetuses. Those who were symmetrical were proportionally small, and
those who were asymmetrical had disproportionally lagging abdominal
growth.
SYMMETRICAL FGR
 Symmetrical FGR occurs as a result of early fetal insult in the
pregnancy. This early fetal insult results in relative decrease in cell
number and size. Symmetrical FGR accounts for 20-30% growth
In utero Growth Status according to Birthweight percentile
Fetal Growth Restriction
restricted fetuses. The causes of symmetrical FGR include viral
infections, chemical exposure or cellular maldevelopment with
aneuploidy may cause a proportionate reduction of both head and body
size.
All parameters, i.e. head and abdominal circumference, length and
weight, are below the 10th percentile for gestational age, hence these
infants have a normal ponderal  index.
            Medical interventions to improve the fetal growth are rarely
effective as the causative factor is usually uncorrectable(8).
ASYMMETRICAL FGR
           Asymmetrical FGR follows a late pregnancy insult such as
uteroplacental insufficiency. It is usually associated with maternal
diseases such as chronic hypertension, renal disease, and vasculopathy.
Resultant diminished glucose transfer and hepatic storage would
primarily affect cell size and not number, and fetal abdominal
circumference-which reflects liver size-would be reduced. Such somatic
growth restriction is proposed to result from preferential shunting of
oxygen and nutrients to the brain, which allow normal brain and head
growth –so-called brain sparing. The fetal brain is normally relatively
large and the liver relatively small. Accordingly, the ratio of brain weight
to liver weight during the last 12 weeks, usually about 3to 1, may be
increased to 5 to 1 or more in severely growth restricted fetuses.   It
accounts for approximately 70-80% of growth restricted fetuses. The
Ponderal index is low with low birth weight and abdominal
circumference, but normal head circumference and fetal length.
 However, in case of severe placental insufficiency the head growth
curve may also be flattened eventually and the size may drop below the
normal growth curve. This type of growth restriction leads to decreased
amniotic fluid, chronic hypoxia and may result in fetal death.
3.  ETIOLOGY AND RISK FACTORS :
FGR may be caused by maternal, placental, or fetal factors.
Approximately one-third of FGRs are due to genetic causes, and two-
thirds are related to the fetal environment. However, no underlying
etiology can be identified in at least 40 percent of SGA infants.
FETAL FACTORS
Genetic factors— Population-based intergenerational studies of birth
weight have found that genetic factors contribute 30 to 50 percent of the
variation in birth weight [9]. Maternal genes influence birth weight more
than paternal genes, but both have an effect. Specific allelic variants
associated with birth weight include mutations in GCK and HNF1beta,
which have been associated with low birth weight, and mutations in
HNF4 alpha, which have been associated with high birth weight. Variants
in ADCY5 and loci near CCNL1 also appear to lower birth weight [10].
The susceptibility to FGR is also heritable; in epidemiologic studies,
women who were SGA themselves at birth have a two-fold increase in
risk of FGR in their offspring [11,12] .Women who give birth to a growth
restricted fetus are at high risk of recurrence, and the risk increases with
increasing numbers of FGR deliveries.
Chromosome Abnormalities - Karyotypic abnormalities account for up
to 20 percent of all FGR [13,14]. The presence of a chromosomal
abnormality often results in restriction of fetal growth early in pregnancy;
as many as one-quarter of fetuses with early onset FGR have
chromosomal abnormalities. Most cases are symmetric, but asymmetric
early FGR also occurs [15]. Chromosomal abnormalities associated with
FGR include [16]:
 Aneuploidy (e.g. trisomy 18 or 13, Turner 45 X, triploidy)
 Partial deletions (e.g. Cri du chat syndrome 5q, Wolf-Hirschhorn
syndrome 4q)
 Ring chromosomes
 Uniparental disomy (e.g. for chromosomes 6, 14, and 16)
 Confined placental mosaicism
 Gene mutations (e.g. mutations in the gene for insulin-like growth
factor)
Multiple gestation— Fetal growth in multiple gestations has a direct
relationship to the number of fetuses present; the type of placentation also
plays a role (monochorionic versus dichorionic). Growth is similar to that
of singletons until the third trimester and then slows. The lower weight of
fetuses from multiple gestations is thought to be due to an inability of the
environment to meet the nutritional needs of multiple fetuses, as well as
pregnancy complications more common in multiple gestation (eg,
maternal undernutrition, preeclampsia, twin-twin transfusion, congenital
anomalies). Placental and umbilical cord anomalies potentially associated
with underperfusion (e.g. velamentous cord insertion) are also more
common in multiple gestations.
Infection— Infections that develop early in pregnancy have the greatest
effect on subsequent growth, but account for less than 5 percent of all
cases of FGR. Viruses and parasites (e.g. rubella, toxoplasmosis,
cytomegalovirus, varicella-zoster, malaria, syphilis, herpes) may gain
access to the fetus transplacentally or across the intact fetal membranes
and impair fetal growth by a variety of mechanisms (e.g. cell death,
vascular insufficiency). Although uncommon, CMV (Cytomegalo Virus)
is the most frequent viral etiology of FGR in developed countries [17].
There is less evidence implicating bacterial infection as an etiology for
FGR, although maternal infection with listeria, tuberculosis, chlamydia,
and mycoplasma has been reported to increase the risk to FGR.
PLACENTAL FACTORS
Many cases of FGR, particularly recurrent cases, are the result of
ischemic placental disease. This term refers to a disease process of the
placenta that clinically manifests as preeclampsia, FGR, abruption, or a
combination of these disorders[18,19]. All of these disorders may be
associated with preterm birth or fetal loss and represent late
manifestations of abnormal placental development dating from the
earliest stages of pregnancy.
Gross and histological lesions—Any mismatch between fetal
nutritional or respiratory demands and placental supply can result in
impaired fetal growth. Studies have suggested that there is significant
excess placental functional capacity. In sheep models, fetal growth is
affected when one-half of the placenta is removed . The human fetus may
be more sensitive to a reduction in placental mass: placental weight is 24
percent smaller in growth restricted fetuses than in normally grown
fetuses when adjustments are made for gestational age [20].
However, placental functional capacity cannot be accurately
assessed from placental weight or dimensions alone. Abnormal
development, narrowing or obstruction of placental vessels, and physical
separation at the maternal interface all impair placental function. The
types, distributions, and sizes of parenchymal and vascular lesions also
play a role; moreover, some maternal disorders (eg, severe maternal
malnutrition or alcohol abuse) can affect fetal nutrition without causing a
recognizable histopathological lesion [21].
Identifiable placental histological abnormalities associated with
fetal undernutrition include abnormalities of the uteroplacental
vasculature (maldevelopment, obstruction, disruption), chronic abruption,
chronic infectious and idiopathic inflammatory lesions (eg, infection
related villitis, chronic villitis of unknown etiology), infarction, distal
villous hypoplasia, massive perivillous fibrin deposition (i.e. maternal
floor infarction), and thrombosis in the uteroplacental, intervillous and/or
fetoplacental vasculature [22].Diffuse chronic villitis of unknown etiology
appears to be the most common placental finding in otherwise idiopathic
FGR [17,22,23].
Gross placental structural anomalies possibly associated with FGR
include single umbilical artery, velamentous umbilical cord insertion,
bilobate placenta, circumvallate placenta, placental hemangioma, and,
possibly, placenta previa.
Confined placental mosaicism—Confined placental mosaicism (CPM)
refers to chromosomal mosaicism (usually involving a trisomy) found in
the placenta, but not in the fetus. It occurs significantly more often in the
placentas associated with FGR than in controls of normal weight.
Approximately 10 percent of placentas associated with idiopathic FGR
have been reported to have CPM [24,25]; the rate of CPM in controls
undergoing CVS is about 1 percent. The extent of FGR depends upon the
chromosomes involved, the proportion of mosaic cells, and the presence
of uniparental disomy [26].
Placentas with CPM have a high ratio of placental infarcts and
decidual vasculopathy, and one-third of placentas with these findings and
FGR have CPM .
MATERNAL FACTORS
Reduction in uteroplacental blood flow—Uteroplacental blood flow
may be diminished by faulty development, acquired obstruction, or
disruption of the uteroplacental vasculature. Maternal medical disorders
(e.g. hypertension, renal insufficiency, diabetes, collagen vascular
disease, systemic lupus erythematosus, antiphospholipid syndrome) and
obstetrical complications (e.g. preeclampsia) associated with
vasculopathy and/or reduced maternal blood volume or blood pressure
diminish uteroplacental perfusion and result in FGR [27].. Preeclampsia, in
particular, is characterized by primary failure of trophoblast invasion of
the spiral arteries leading to failure of dilatation of these vessels, acute
atherosis, occlusion, and infarction.
Constitutionally small mothers
If a women begins pregnancy weighing less than 100 pounds, the
risk of delivering an SGA infant is increased at least twofold (simpson
and colleagues, 1975). Moreover, intergenerational effects on birthweight
are transmitted through the maternal line such that reduced intrauterine
growth of the mother is the risk factor for reduced intrauterine growth of
her offspring.
Diminished caloric intake—Maternal weight at birth, prepregnancy
weight, and weight gain during pregnancy are generally responsible for
about 10 percent of the variance in fetal weight [28]. However, severe
maternal starvation during pregnancy can have a major impact on fetal
growth. As an example, the Dutch population suffered severe famine
during the winter of 1944 to 1945; mean maternal caloric intake fell to
450 to 750 kcal a day. As one result of this deprivation, average infant
birth weight during this period decreased by 250 grams. Similarly, in
Leningrad during the World War II German siege, which resulted in a
longer and more profound starvation period (down to 300 kcal of mostly
carbohydrates and no protein), average birth weight fell by more than 500
grams.
Modest degrees of nutritional deficiency also have an effect on birth
weight. Women who are underweight at the start of pregnancy or have
poor weight gain during pregnancy are at higher risk of delivering an
infant weighing less than 2500 grams.
Hypoxemia—Chronic maternal hypoxemia due to pulmonary disease,
cyanotic heart disease, or severe anemia is associated with diminished
fetal growth. As an example, a study of 96 pregnancies in women with
cyanotic congenital heart disease reported that the mean birth weight of
full term infants was only 2575 grams, which is significantly lower than
the mean birth weight of 3500 grams in the general population [29].
Residing at high altitude also results in a chronic hypoxemic state
and lower birth weight. A direct relationship between increasing altitude
and lower birth weight has been demonstrated. Birth weight data from 15
areas in Peru located anywhere from sea level to 4575 meters showed
birth weight declines an average of 65 grams for every additional 500
meters in altitude above 2000 meters[30]. The fetus can compensate for
hypoxemia in a number of ways, including redistribution of circulation to
vital organs and deferment of growth, decreased gross body movements,
and increasing tissue oxygen extraction. The exact level and duration of
fetal hypoxemia that exceed these compensatory mechanisms are not
defined in humans.
Hematological and immunologic disorders—Hematological disorders,
such as sickle cell disease, may cause thrombosis of the intervillous
space. Autoimmune and alloimmune disorders (e.g. antiphospholipid
syndrome) may cause chronic villitis, as well as vasculopathy. Fetal
undernutrition and hypoxia are possible sequelae.
Substance use and cigarette smoking—Maternal substance use,
including cigarette smoking, alcohol consumption, and illicit drug use can
cause FGR either by a direct cytotoxic effect or indirectly from related
variables, such as inadequate nutrition.
Smoking during the third trimester appears to have the greatest
impact on birth weight; women who quit smoking by the third trimester
have birth weights similar to those of nonsmokers [31].
Toxins— Toxic exposures, including various medications such
as warfarin, anticonvulsants, antineoplastic agents, and folic acid
antagonists,  can produce FGR with specific dysmorphic features [32,33].
Fetal exposure to therapeutic, but not diagnostic, doses of radiation
can cause permanent restriction of growth. Prepregnancy radiation
therapy to the pelvis can result in anatomic changes in the pelvic
vasculature that may lead to reduced fetoplacental perfusion and growth
restriction.
Assisted reproductive technologies :
Singleton pregnancies conceived via assisted reproductive
technologies have a higher prevalence of both low birth weight and SGA
infants compared with naturally conceived pregnancies.
Others:
 FGR is more common among pregnancies at the extremes of
reproductive life.
 Uterine malformations may affect uteroplacental perfusion and
result in FGR
 A short interpregnancy interval has been associated with low birth
weight and FGR, and this may be mediated through a relative
depletion in folic acid.
 Chronic maternal stress may also be a factor . Chronic stress is
associated with elevated corticotropin-releasing hormone (CRH)
levels, which, in turn, may be associated with impaired fetal
growth and preterm birth.
4.  PATHOPHYSIOLOGY[34]
Interference with placental nutrient supply can affect all aspects of
placental function. The gestational age at onset, the magnitude of the
injury, and the success of adaptive mechanisms determine the ultimate
severity. Mild placental disease is more likely to affect organ function
and maturation at the cellular level, with little perceivable growth delay
perinatally, but may affect adult health (fetal programming), often
through epigenetic modifications. With more severe placental disease,
fetal growth delay and adaptive organ responses become evident in utero.
MECHANISMS OF PLACENTAL DYSFUNCTION
The efficiency of maternal to fetal exchange of nutrients, fluid, and
waste can become suboptimal when there is a decrease in substrate
transporters, an increase in the diffusion distance between maternal and
the fetal compartments, a decrease in the exchange area or impedance to
blood flow in the maternal and fetal compartments in the placenta.
Typically, trophoblast invasion is confined to the decidual portion of
myometrium, and the spiral and radial arteries do not transform into low-
resistance vessels.
Altered expression of vasoactive substances increases vascular
reactivity, and if hypoxia-stimulated angiogenesis is inadequate, placental
autoregulation becomes deficient. Maternal placental floor infarcts and
Pathophysiology of FGR
fetal villous obliteration and fibrosis increase placental blood flow
resistance, producing a maternal-fetal placental perfusion mismatch that
decreases the effective exchange area.
The severity of placental vascular dysfunction is clinically assessed
in the maternal and fetal compartments of placenta with Doppler
ultrasound. An early diastolic notch in the uterine arteries at 12-14 weeks
suggests delayed trophoblast invasion, whereas persistence of “notching”
beyond 24 weeks provides confirmatory evidence.
METABOLIC AND CELLULAR EFFECTS OF PLACENTAL
DYSFUNCTION
Oxygen and glucose consumption by the placenta is unaffected
when nutrient delivery to the uterus is only mildly restricted and the fetal
demands can be met by increased fractional extraction. Fetal
hypoglycemia occurs uterine oxygen delivery and likely substrate
delivery is less than a critical value and fetal oxygen uptake is reduced.
Insulin is an important fetal growth factor. Fetal pancreatic insulin
responses are blunted by mild hypoglycemia, allowing gluconeogenesis
from hepatic glycogen stores. At this stage, fetal glucose stores and
lactate are preferentially diverted to the placenta to maintain placental
metabolic, endocrine, and nutrient transfer function . Hypoglycemia,
hyper lactic acidemia , and growing base deficit correlate with the degree
of fetal hypoxemia and protein energy malnutrition. Down-regulation of
several cellular transporters and the Na/H+ pump affects placental
cellular function. Simultaneously, the principle endocrine growth
axis(insulin and insulin like growth factors) as well as leptin-coordinated
fat deposition is down-regulated.
FETAL RESPONSE IN MAJOR ORGANS
Enhanced blood flow to the individual organs is documented in the
myocardium, spleen, and liver. Conversely, blood flow resistance in the
peripheral pulmonary arteries, celiac axis, mesenteric vessels, kidneys,
and femoral and iliac arteries increases. The overall effect is an improved
distribution of well-oxygenated blood to vital organs, with preferential
streaming of descending aorta blood flow to the placenta for
reoxygenation. There is progressive decrease in the amniotic fluid volume
after long-standing redistribution.
A delay occurs in all aspects of central nervous system maturation
in fetuses with chronic hypoxemia. There is also a progressive decline in
global fetal activity. This results in higher baseline heart rate, with lower
short- and long-term variation.
FETAL DECOMPENSATION
If placental dysfunction is progressive or sustained, the adaptive
mechanisms become exhausted and decompensation begins. Multiple-
organ failure as a result of placental dysfunction is caused by the
metabolic milieu and the regulatory loss of cardiovascular hemostasis.
Metabolic abnormalities are exaggerated , acidemia worsens, and the risk
of intrauterine damage or perinatal death increase dramatically.
5. DIAGNOSIS OF FGR
Diagnosis of FGR is important because it has demonstrable effects
on  survival and development of fetus.
CLINICAL ASSESSMENT
Clinical assessment is a reasonable screening tool for FGR in low
risk pregnancies. Clinical assessment is based on assessment of past and
present risk factors, physical examination, and ultrasound studies.
Accurate assessment of gestational age—Accurate knowledge of
gestational age (GA) is critical to the diagnosis of FGR, given that normal
and abnormal fetal size are defined, in part, by comparing the fetal weight
of the index fetus to that of other fetuses of the same gestational age.
Symphysis-fundal height measurement—Serial measurement of the
distance between the upper edge of the pubic symphysis and the top of
the uterine fundus using a tape measure is a simple, inexpensive, and
widespread procedure performed during antenatal care to detect fetuses
that are poorly grown. Between 18 and 30 weeks, the symphysis-fundal
height in centimeters coincides within 2 weeks of gestational age.  The
first suspicion of FGR often arises when this length is noted to be
discordant with the expected size for dates, that is at least three
centimeters below the GA in weeks (eg, fundal height 32 cm at 36 weeks
of gestation) (42).
The accuracy of fundal height measurements for screening and
diagnosis of FGR is controversial; Observational studies using
symphysis-fundal height measurements have reported a wide range of
sensitivities: 28 to 86 percent of small fetuses were detected [35-38].
Abdominal palpation—Clinical assessment of fetal size by abdominal
palpation does not perform well as a test for detecting FGR: sensitivities
range from 30 to 50 percent [38,39,44].
SONOGRAPHIC SCREENING AND DIAGNOSIS
An initial sonographic examination at 16-20weeks followed by a
second examination  at 32-34weeks serial  sonography should serve to
identify many cases of fetal growth restriction (Ewigman and
colleagues,1993).
Commonly used parameters include biparietal diameter, head
circumference, abdominal circumference, femur length and various
morphometric ratios like  HC/AC, and FL/AC. Ultrasound results need to
be interpreted in terms of pretest risk of FGR and take into account
whether the subject population was at low, moderate, or high risk of fetal
growth abnormality.
The morphometric tests are more likely to overlook fetuses with
symmetric FGR, but can be used as confirmatory tests of suspected
asymmetric FGR. As discussed above, symmetric FGR comprises 20 to
30 percent of growth restricted fetuses and asymmetric FGR occurs in the
remaining 70 to 80 percent of the FGR population.
Abdominal circumference—When fetal growth is compromised, the
fetal abdominal circumference (AC) is smaller than expected because of
depletion of abdominal adipose tissue and decreased hepatic size related
to reduced glycogen storage in the liver. An abdominal circumference
within the normal range for gestational age reliably excludes growth
restriction, whereas a measurement less than 5th percentile is highly
suggestive of growth restriction (American College of Obstetricians and
Gynecologists, 2000b).
Studies report that reduced AC is the most sensitive single
morphometric indicator of FGR[40-43]. The performance of AC
measurement was illustrated by a study of 3616 pregnancies over 25
weeks of gestation that had a single ultrasound examination performed
within two weeks of delivery [45]. AC measurement predicted small for
gestational age (SGA) infants (i.e., birth weight below the 10th percentile
for GA) with sensitivity, specificity, positive and negative predictive
values of 61, 95, 86, and 83 percent, respectively.
Measurement of AC was more predictive of FGR than
measurement of either head circumference (HC) or biparietal diameter
(BPD) or the combination of AC with either one of these two variables.
The optimal time to screen for FGR was at approximately 34 weeks of
gestation.
The following factors affect the sensitivity of the AC measurement:
 Symmetric versus asymmetric growth abnormality. AC is more
sensitive in asymmetric FGR. [46].
 Gestational age. AC is more sensitive later in gestation. [47].
 Time interval between AC measurements. AC is more sensitive
when the interval between measurements is more than two
weeks[48].
MEASUREMENT OF ABDOMINAL CIRCUMFERENCE:
The abdominal circumference is obtained in the transaxial view of
the fetal abdomen, at the level of fetal liver, using umbilical portion of the
left portal vein as a landmark. The fetal stomach is at the same level,
which is slightly caudal to the fetal heart and cephalad to the kidneys.
ABDOMINAL CIRCUMFERENCE
Umbilical venous circulation through the fetal liver. A. Plane of section depicting the
umbilical vein (UV) in short axis.This plane is too caudal for abdominal
circumference measurement. B. Plane of section through the junction of the left
(LPV) and right (RPV) portal veins.This is the correct level for AC measurement
(DV, ductus venosus). C. Plane of section aligned along the course of the LPV.Note
that this plane is too inclined in a craniocaudal axis. (Illustration by James A. Cooper,
MD, San Diego, CA.)
Plane of measuring abdominal circumference
Sonographic appearance of the cerebellum through gestation
Normal Range for Abdominal Circumference
Abdominal Circumference (mm)Gestational agerange
(weeks + days) 5th centile Median 95th centile
14+0-14+6 80 90 102
15+0-15+6 88 99 112
16+0-16+6 96 108 122
17+0-17+6 105 118 133
18+0-18+6 114 128 144
19+0-19+6 123 139 156
20+0-20+6 133 149 168
21+0-21+6 143 161 181
22+0-22+6 153 172 193
23+0-23+6 163 183 206
24+0-24+6 174 195 219
25+0-25+6 184 207 233
26+0-26+6 195 219 246
27+0-27+6 205 231 259
28+0-28+6 216 243 272
29+0-29+6 226 254 285
30+0-30+6 237 266 298
31+0-31+6 246 277 310
32+0-32+6 256 287 322
33+0-33+6 265 297 334
34+0-34+6 274 307 345
35+0-35+6 282 316 355
36+0-36+6 289 324 364
37+0-37+6 295 332 372
38+0-38+6 302 339 380
39+0-39+6 307 345 387
Gestational Age (Weeks)
Estimated fetal weight (EFW) : Fetal weight estimation has become one
of the most common methods of identifying the growth-restricted fetus.
Equations that incorporate AC, BPD, and FL seem to provide the most
accurate estimates of fetal weight[49]. In general, estimated fetal weight
measurements are within 10 percent of the actual birthweight in 75
percent of patients in whom there is a clinical suspicion of FGR.
The average sensitivity, specificity, positive and negative
predictive values for FGR using these parameter are approximately 90,
85, 80, and 90 percent, respectively [55-58]. The sensitivity is generally
higher for infants with severe growth restriction (birth weight less than
the 3rd percentile). But this can diagnose FGR only when the gestational
age is known.
Customized growth curves— EFW is typically classified using
population-based birth weight centiles. Several studies have compared the
use of population-based birth weight centiles to customized centiles for
prediction of SGA and perinatal morbidity. These studies have generally
concluded that using a customized birth weight standard increases the
identification of fetuses at risk of perinatal death and neonatal morbidity.
This improvement in prediction of outcome may be related to better
identification of the constitutionally small fetus through adjustment for
maternal characteristics, or to use of an intrauterine (ultrasound) growth
BIRTH WEIGHT PERCENTILE
Age (wk) 5th 10th 50th 90th 95th
20 249 275 412 772 912
21 280 314 433 790 957
22 330 376 496 826 1023
23 385 440 582 882 1107
24 435 498 674 977 1223
25 480 558 779 1138 1397
26 529 625 899 1362 1640
27 591 702 1035 1635 1927
28 670 798 1196 1977 2237
29 772 925 1394 2361 2553
30 910 1085 1637 2710 2847
31 1088 1278 1918 2986 3108
32 1294 1495 2203 3200 3338
33 1513 1725 2458 3370 3536
34 1735 1950 2667 3502 3697
35 1950 2159 2831 3596 3812
36 2156 2354 2974 3668 3888
37 2357 2541 3117 3755 3956
38 2543 2714 3263 3867 4027
39 2685 2852 3400 3980 4107
40 2761 2929 3495 4060 4185
41 2777 2948 3527 4094 4217
42 2764 2935 3522 4098 4213
43 2741 2907 3505 4096 4178
44 2724 2885 3491 4096 4122
         Source : Alexander and associates (1996).
standard rather than a birth weight standard for classification of FGR.
Since fetuses who are born preterm tend to have lower birth weights that
fetuses of the same gestational age who remain inutero, using an
intrauterine weight standard increases identification of FGR remote from
term.
Growth velocity—As discussed above, the use of any parameter (eg,
AC, EFW) in the prediction of FGR is based upon accurate assessment of
GA. If dates are unknown, serial sonographic examinations at two-week
intervals should be performed to evaluate the rate of interval growth (ie,
growth velocity). Irrespective of GA, there is a significantly lower rate of
change over time of AC or EFW in FGR fetuses compared with those
fetuses whose growth is appropriate for GA . In one study, as an example,
a change in fetal AC of less than 10 mm over a two-week period had a
sensitivity of 85 percent and specificity of 74 percent for identifying
FGR[50]. Fetuses with normal growth velocity are at low risk of
complications associated with FGR.
Body proportions— The HC/AC ratio, FL/AC ratio, and ponderal index
have also been used to identify the growth restricted fetus, particularly in
the setting of asymmetric FGR.
HC/AC ratio— The HC/AC ratio has been proposed for evaluating
fetuses with asymmetric FGR. In these infants, the size of the liver tends
to be disproportionately small compared to the circumference of the head
or length of the femur, which are initially spared from the effects of
nutritional deficiency.
The HC/AC ratio decreases linearly throughout pregnancy and a
ratio greater than 2 standard deviations (SD) above the mean for GA is
considered abnormal. The sensitivity, specificity, positive and negative
predictive values of an abnormal HC/AC in a population with FGR of
mixed etiologies were 36, 90, 67, and 72 percent, respectively [51]. These
findings demonstrate that an abnormal HC/AC ratio is more accurate in
predicting FGR related to uteroplacental insufficiency (often asymmetric)
than FGR from other etiologies (often symmetric). However, not all
fetuses with an elevated HC/AC ratio have FGR. As an example,
macrocephaly could also be associated with an abnormal HC/AC, which
would be unrelated to FGR.
FL/AC ratio— The FL/AC ratio uses sonographic elements that relate
to both weight and length in the prediction of FGR. An FL/AC ratio
greater than 23.5 percent has a sensitivity of 56 to 64 percent and
specificity of 74 to 90 percent for identification of asymmetric FGR[52].
This ratio is independent of GA in normally grown fetuses in the last half
of pregnancy. However, an abnormal FL/AC ratio does not accurately
diagnose symmetric FGR. The sensitivity, specificity, positive and
negative predictive values of the 90th percentile of FL/AC ratio in a
mixed population of FGR fetuses were 30, 91,14, and 96 percent,
respectively[53].
Therefore, the FL/AC ratio is unsuitable for screening for FGR in
the general population.
Ponderal index:
PI is often used as an index (ie, PI = [weight (in g) x 100] ÷ [length
(in cm)](3) to define growth restriction(54). A fetal PI has been calculated
based upon a sonographically derived EFW and measurement of the FL.
One study reported sensitivity, specificity, and positive predictive value
of the fetal PI for FGR of 77, 82, and 36 percent, respectively; however,
there was a poor correlation between fetal and neonatal PI [55).
With normal growth, the PI increases gradually from 30 to 37
weeks gestation and then remains constant. Decreased growth of adipose
tissue and skeletal muscle, the major contributors to body weight, results
in a reduced PI. Reductions in PI or other indices, such as the ratio of
mid-arm to occipito-frontal circumference, can identify growth restriction
in newborns whose weight is greater than the 10th percentile. PI of less
than 10th percentile reflects fetal malnutrition; PI of less than third
percentile indicates severe wasting .
Amniotic fluid volume—Oligohydramnios refers to amniotic fluid
volume that is less than expected for gestational age. It is typically
diagnosed by ultrasound examination and may be described qualitatively
or quantitatively by various methods.
Oligohydramnios is one of the sequelae of FGR. The proposed
mechanism is diminished fetal urine production due to hypoxia-induced
redistribution of blood flow to vital organs at the expense of less vital
organs, such as the kidney[56]. Oligohydramnios  commonly occurs with
complications of pregnancy other than FGR. In addition, a significant
proportion (approximately 15 to 80 percent) of fetuses with FGR do not
have decreased amniotic fluid volume. Therefore, oligohydramnios is a
poor screening modality for suboptimal growth [43,57]. However, if it is
present in the absence of ruptured membranes, congenital genitourinary
anomalies, or prolonged pregnancy, FGR is the most likely etiology.
Soft tissue measurements— FGR results in a decrease in both adipose
tissue and muscle mass. Measurement of fetal soft tissue is probably
predictive of FGR; however, there are inadequate data for defining the
best site for measurement or the sensitivity and specificity of this
parameter.
Doppler velocimetry—Doppler ultrasound is a noninvasive technique
commonly used to evaluate maternal and fetal hemodynamics.
Continuous, adequate perfusion of the maternal and fetal sides of the
placenta is necessary for normal fetal growth. FGR is associated with
diminished flow and abnormal Doppler waveforms in both maternal and
fetal vessels. Doppler has been useful in evaluation and management of
pregnancies suspected of FGR. Not all infants whose birth weight is
below the 10th percentile have been exposed to a pathological process.
Most small newborns are constitutionally small and healthy.
Differentiating the fetus with pathological growth restriction who is at
risk for perinatal complications from the constitutionally small, but
healthy, fetus has been an ongoing challenge in obstetrics. This is the
setting in which Doppler is useful because it can distinguish between
these two groups[58,59] and guide timing of interventions (eg, intensive
monitoring, antenatal glucocorticoids, early delivery) that reduce
perinatal mortality.
Venous Doppler assessment has been studied less extensively, and
is used for monitoring, rather than diagnosis, of FGR.
Uterine artery—Uterine artery Doppler flow velocimetry has limited
diagnostic accuracy for prediction of FGR and is not useful as a screening
tool.
The shape of the uterine artery velocity waveform is unique: it is
characterized by high end-diastolic velocities with continuous forward
blood flow throughout diastole. As GA advances, the degree of end-
diastolic flow typically increases; however, failure of normal
endovascular trophoblastic invasion of the spiral arteries results in
increased uterine artery vascular resistance and decreased perfusion of the
placenta . Preeclampsia and/or FGR often subsequently develop [60].
The systolic/diastolic (S/D) ratio of the uterine artery in normal
pregnancies should be less than 2.7 after the 26th week of gestation. If the
end-diastolic flow does not increase throughout pregnancy or a small
uterine artery notch is detected at the end of systole, the fetus is at high
risk for developing FGR. Diastolic blood flow may be absent or even
reversed with extreme degrees of placental dysfunction. Such findings are
ominous and may precede fetal death or signal a high risk of abnormal
fetal neurologic outcome.
Umbilical artery—Doppler umbilical artery studies are not useful for
screening and diagnosis of FGR. Comparative studies are scarce, but
support this conclusion.
Fetal cerebral arteries—Doppler evaluation of fetal cerebral arteries is
not useful in the initial diagnosis of FGR, but may be useful confirming
the diagnosis and evaluating the FGR fetus. In the normally developing
fetus, the brain is an area of low vascular impedance and is the recipient
of continuous forward flow throughout the cardiac cycle. Asymmetric
FGR is likely caused by redistribution of fetal blood flow to the fetal
brain, at the expense of less essential areas such as subcutaneous tissue,
kidneys, and liver. However, the already low cerebral resistance has to
drop even further to enhance cerebral blood flow. This has been measured
as increased end diastolic velocities and decreased S/D ratios in the
cerebral arteries of growth restricted fetuses[62].
Venous Doppler—Venous Doppler has no role in diagnosis of FGR
since venous Doppler abnormalities constitute a late circulatory finding.
Venous Doppler assessment is used for monitoring fetal well-being; use
of this technique appears to significantly improve the prediction of
stillbirth and acidemia over use of umbilical artery Doppler alone.
6. THE NORMAL CEREBELLUM [63,64]
Cerebellum is located in the posterior fossa and consists of two
hemispheres connected by the vermis.  Cerebellum is peanut shaped with
central constriction denoting the vermis and flared ends representing two
hemispheres. Its location in the posterior fossa (surrounded by the dense
petrous ridges and occipital bone) makes it more resistant to deformation
by extrinsic pressure. It has therefore been proposed that the transverse
cerebellar diameter is a better predictor predictor of gestational age than
the BPD when there are variations in the shape of the fetal head
(dolicocephaly or brachycephaly). On ultrasound, the cerebellar
hemispheres are normally echo-poor to moderately echogenic, bounded
superiorly by the echogenic tentorium cerebella. Cistern magna is a fluid
collection posterior to the cerebellum. The vermis separates the cisterna
magna from the fourth ventricle.
Can be sonographically visualized as early as 9-10 weeks.  It grows
rapidly in the second trimester having a linear relationship with
gestational age. Measurement in mm approximately equals the gestational
age in weeks.
In prenatal ultrasound , an axial plane 15 to 30 degrees from the
canthomeatal line visualizes both the cerebellum and cistern magna. This
plane is usually reached by starting with the level where the standard
BPD is obtained, then exaggerating the posterior tilt of the transducer to
include the cerebellum. Measurement of the nuchal skin can also
performed at this level in the early second trimester. The “banana sign” in
fetuses with chiari 2 malformations is also seen at this level. Where the
cerebellar hemispheres become oriented anteriorly and appear to wrap
around the cerebral peduncles giving rise to the elongated crescentic
“banana”.
.
GRADES OF CEREBELLUM
Grade 1:
 Seen predominantly upto 27 weeks of gestation.
 Cerebellar hemisphere is rounded and lacks echogenicity.
 Vermis poorly developed giving the cerebellum the
appearance of an “eyeglass”.
Grade 2:
 Seen predominantly from 28-32 weeks of gestation .
 Vermis more prominent and appears as an echogenic
rectangular tissue connecting both hemispheres.
 Cerebellar hemisphere is oval and the central portion is more
echogenic than the peduncles but less echogenic than the
circumferential margin of the hemisphere.
 Cerebellum has “dumbbell” appearance
Grade 3:
 Seen predominantly after 32  weeks of gestation.
 Hemispheres become triangular or “fan-shaped”.
 Echo pattern from the central portion of the hemisphere is
now similar to the margin of the vermis.
 Cerebellum now looks more solid than cystic
Transverse Cerebellar Diameter
           The cerebellum can be measured in an axial plane using the
transverse outer-to-outer margins. There is high degree of correlation
between TCD and gestational age .  Prior to 24 weeks the transverse
cerebellar diameter in millimeters is equivalent to the gestational age in
weeks following which there is a flattening of the growth curve[65].
Cerebellum is the last organ affected by decrease in the blood flow.
In acute asphyxia, cerebellar blood flow remains unchanged as a
consequence of redistribution of cardiac output[66]. To assess the fetal
growth TCD has been one of the most reliable parameters in assessing the
growth and gestational age estimation[67]. Thus TCD may serve as an
independent indicator of GA against which other potential deviations of
growth may be compared.
MEASUREMENT OF TRANSVERSE CEREBELLAR DIAMETER:
McLeasy et al (1984) and Goldenstein et al (1987) described the
technique for measuring TCD, in which the usual thalamic plane used for
BPD is obtained, the transducer is then rotated about 300  from reids
baseline demonstrated the contents of posterior fossa. In all cases, the
widest diameter of the cerebellum was measured.
The vermis of the cerebellum, cerebellar hemispheres, cisterna
magna and the nuchal translucency are seen in this plane. The cerebral
peduncles, the falx cerebri and the cavum septum pellucidi are imaged in
the midline.
PREDICTED MENSTRUAL AGE ACCORDING TO
TRANSVERSE CEREBELLAR DIAMETER MEASUREMENTS
Cerebellum
(mm)
Menstrual Age
(Week)
Cerebellum
(mm)
Menstrual Age
(Week)
14 15.2 35 29.4
15 15.8 36 30.0
16 16.5 37 30.6
17 17.2 38 31.2
18 17.9 39 31.8
19 18.6 40 32.3
20 19.3 41 32.8
21 20.0 42 33.4
22 20.7 43 33.9
23 21.4 44 34.4
24 22.1 45 34.8
25 22.8 46 35.3
26 23.5 47 35.7
27 24.2 48 36.1
28 24.9 49 36.5
29 25.5 50 36.8
30 26.2 51 37.2
31 26.9 52 37.5
32 27.5 53 38.0
33 28.1 54 38.3
34 28.8 55 38.5
Plane of measuring transverse cerebellar diameter
TCD/AC RATIO
This ratio compares the most preserved organ in the malnourished
fetus, the cerebellum with the most compromised organ, liver,
represented by fetal AC. In normally grown fetuses, there is a strong
linear correlation with TCD measurement and AC. The TCD/AC ratio
remains fairly constant throughout gestation. A value exceeding 2 SD of
the mean was significantly associated with birth of small-for-gestational
age infant, being abnormal in 98% and 71% of asymmetrically and
symmetrically growth-retarded infants respectively[69].
CALCULATION OF THE TCD/AC RATIO%:
TCD/ AC ratio% = TCD in cm /AC in cm  x 100
7. PERINATAL OUTCOME
Fetal growth restriction is the second leading cause of perinatal
morbidity and mortality, followed only by prematurity.  In assessing
Centile Chart for TCD
Relationship between Birth weight percentile and perinatal mortality
and morbidity in SGA
perinatal outcome by weight, infants who weigh less than  2,500 g
(5 lb, 8 oz) at term have a perinatal mortality rate that is five to 30 times
greater than that of infants whose birth weights are at the 50th percentile.
The mortality rate is 70 to 100 times higher in infants who weigh less
than 1,500 g (3 lb, 5 oz). Perinatal asphyxia involving multiple organ
systems is one of the most significant problems in growth-restricted
infants. Timely diagnosis and management of IUGR is one of the major
achievements in contemporary obstetrics. If the growth-restricted fetus is
identified and appropriate management instituted, perinatal mortality can
be reduced, underscoring the need for assessment of fetal growth at each
prenatal visit.
REVIEW OF CLINICAL STUDIES
Reece et al (1987) stated that transverse cerebellar diameter was
unaffected by IUGR, thus this nomogram measurement  may serve as an
independent and reliable correlate of gestational age against  which
potential deviations of growth may be compared[70] .
Mikovic and Markovic et al (1989) studied the growth of the fetal
cerebellum  in normal pregnancy between 20 and 40 weeks and  proposed
that TCD can be practically applied  in cases where it is  difficult or
impossible to measure BPD or in cases where it is unsuitable because  of
expressed moulding of head. Since the cerebellum is not liable to changes
in its form and size as it is protected very well in the calvarium. It was
found that there was a good correlation between multiple growth
parameters and TCD.  They proposed that the potential importance of
TCD in the diagnosis of fetal intrauterine growth restriction is based on
the assumption that the cerebellum is not liable or at least not considered
liable for growth restriction[71].
Campbell (1991) done a prospective study in 162 patients, and
measurement of  TCD and AC was obtained between 15 to 38 weeks of
gestation. The ratio between the TCD and AC was calculated. The mean
ratio was 13.7%. This ratio remained constant during gestation[72].
Guan et al in 1992 generated a nomogram for TCD with respect to
gestational age and compared fetal TCD, BPD, HC,AC and FL
measurements by ultrasound. Correlation coefficient between the birth
weight and their parameters were studied and  concluded that the function
of the  cerebellar diameter in the evaluation of  fetal growth and
development is  better than any  other parameter .When combined  with
the abdominal  circumference,  the TCD may help to differentiate  the
types of growth restricted  fetuses.
Campbell (1994) measured TCD, BPD, HC, AC, and FL using
Hadlock’s method of measurement and calculated TCD/AC ratio. The
biometric measurements of the IUGR   fetuses were significantly smaller
than the non-IUGR fetuses.  The TCD is the only measurement that has a
significant difference in the fetuses with IUGR compared to those who
were not growth retarded. The IUGR fetuses had a larger TCD/AC ratio,
the ratio value was greater than 15.9%. The sensitivity and specificity
was 71% and 77% respectively and PPV 79% and NPV 68% for
identification of IUGR cases. However 57% cases missed had severe
growth restriction and not very useful in such cases[74].
T Tongsong et al (1999) analysed 167 pregnancies with suspected
IUGR. The prevalence of IUGR among study group was 51.5%. The best
cut off value of the TCD/AC ratio for predicting IUGR was 15.4%,
giving the sensitivity, specificity, PPV and NPV of 73.26%, 80.25%,
79.75%, and 73.86% respectively. Concluded that the sonographic fetal
TCD/AC ratio as a gestational age independent method can be helpful in
antenatal diagnosis of IUGR, especially in pregnancies with uncertain
gestational age[75].
Dilmen et al (1996) prospectively studied 330 pregnant women
and measurements of TCD, AC, BPD, HC and TCD/AC ratio and HC/AC
ratio were obtained between 16 and 41 weeks of gestation. The
measurement of TCD had a very close relation to the gestational age. The
TCD/AC ratio was calculated and found to be 0.1436+ 0.0106 (SD)
which remained fairly constant throughout pregnancy. The 5th and 95th
percentiles were 0.1279 and 0.1603. Ten of eleven fetuses with TCD/AC
ratios exceeding 2 SD (0.1648) were found to have asymmetrical
intrauterine growth retardation upon neonatal examination. The TCD/AC
ratio is valuable in identifying babies with asymmetrical IUGR in patients
with SGA[76].
Vinkesteijn et al (2000) conducted a retrospective cross sectional
study of the normally developing fetus with TCD increasing with
advanced gestational age. A gestational age related normal reference
chart was produced for TCD and concluded that increased TCD/AC
values were suspicious of fetal growth restriction. The perinatal mortality
in growth restricted fetuses with a small cerebellum was was increased
twofold over that of other fetuses[77].
Malik et al (2003) measured TCD, AC and calculated TCD/AC
ratio in pregnant women. The TCD/AC ratio was found to be 0.14064+
0.059(SD) which remain fairly constant throughout gestation and thus it
is a gestational age independent parameter. TCD was found to be an
accurate parameter and it showed 92% accuracy in predicting GA.
TCD/AC ratio was found to be a good tool to diagnose asymmetric
IUGR. It was almost 100% accurate in diagnosing asymmetric IUGR in
those with ratio exceeding 2 SDs[68].
Materials
and
Methods
MATERIALS AND METHODS
A prospective study consisting of 100 antenatal women was
conducted in Government RSRM Lying  In Hospital,  Stanley medical
college, Chennai during the period from November  2010 to October
2011.
INCLUSION CRITERIA
 Antenatal women with singleton live intrauterine gestation
 Antenatal women with excellent dates
EXCLUSION CRITERIA
 Antenatal women with unreliable dates
 Antenatal women with fetal anomalies
 Antenatal women with multiple gestations
METHODS
Antenatal women were enrolled after written informed consent.
A detailed history of the patients was taken. A thorough systemic and
obstetric examination was made. All preliminary investigations were
done. The antenatal women were made aware of the benefits of
ultrasonogram.  These women were offered ultrasonogram   between
20-22 weeks of gestation. The scans were carried out by the trained
sonologist. With ultrasonogram the transverse cerebellar diameter (TCD)
and abdominal circumference (AC) of fetus were measured in addition to
anomaly scanning, routine biometric parameters and liquor volume. The
TCD/AC ratio was calculated. These women were informed about the
results of the scan. These women were informed to come between 32-34
weeks for repeat scan. The patients were followed up till delivery. All
babies at birth were assessed by the neonatologist and grouped as
appropriate for gestational age (AGA) or fetal growth restriction (FGR)
according to birth weight 10th -90th  percentile and <10th  percentile for
gestational age respectively. The babies were typed as symmetric or
asymmetric IUGR  based on ponderal index. Apgar score, NICU
admission in days and perinatal outcome were noted. The cut-off of value
of TCD/AC ratio for diagnosing FGR arrived by finding mean+2SD of
TCD/AC ratio of AGA fetuses.
STATISTICAL ANALYSIS:
Statistical analysis was performed with SPSS software (version
15.00 for windows). To find out the statistical significance, linear
regression, one way ANOVA (analysis of variance) test and student ‘t’
test was done. For the purpose of this study 95% confidence interval has
been chosen and ‘p’ value <0.05 has been taken as significant.
INTERPRETATION
The TCD/AC ratio >2SD considered to be at risk of having fetal
growth restriction. Women who had TCD/AC >2SD at 20-22 weeks are
considered to be at risk of symmetric FGR and at 32-34 weeks for
asymmetric FGR.
Results
and
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RESULTS AND ANALYSIS
TABLE1: MATERNAL AGE DISTRIBUTION
Maternal  Age in
Years Number of Cases Percentage
18-20 10 10%
21-25 57 57%
26-30 29 29%
>30 4 4%
Most of the antenatal women (57%) of antenatal women were in
the age group of 21-25 years.
TABLE 2: PARITY
PARITY NO OF CASES PERCENTAGE
PRIMI 63 63%
MULTI 37 37%
63% of antenatal women were primigravida.
TABLE 3: RISK FACTORS
AGA FGR
RISK FACTORS NUMBEROF CASES Number Percentage Number Percentage
Preeclampsia 7 4 4.5% 3 30%
Oligohydramnios 3 1 1.1% 2 20%
Preeclampsia &
Oligohydramnios 2 0 0% 2 20%
GDM 2 2 2.2% 0 0%
Chronic hypertension 1 0 0% 1 10%
No Risk Factors 85 83 92.2% 2 20%
30% of FGR  were associated with preeclampsia, 20% with
oligohydramnios and 20% with both risk factors.
TABLE 4 : GESTATIONAL AGE AT DELIVERY
AGA FGRGestational
age at
delivery in
Weeks
Number
of cases Number Percentage Number Percentage
34-36 6 4 4.4% 2 40%
37-40 94 86 95.6% 8 80%
Total 100 90 100% 10 100%
Preterm deliveries were high in FGR (40%) where as in AGA, it
was only 4.4%.
TABLE 5: MODE OF DELIVERY
AGA FGRMode of
Delivery
Number of
cases Number Percentage Number Percentage
Vaginal 69 64 71% 5 50%
LSCS 31 26 29% 5 50%
Total 100 90 100% 10 100%
50% of pregnancies with Fetal Growth Restriction needed delivery
by LSCS whereas only 29% of pregnancies with appropriate fetal growth
needed LSCS.
TABLE 6: IN UTERO GROWTH  STATUS BASED ON PERCENTILE OF BIRTH
WEIGHT
In utero growth
Status No of Cases Percentage Percentile
FGR 10 10% <10th
AGA 90 90% 10-90th
LGA 0 0 >90th
In our study, 10% of babies were FGR according to the birth
weight percentile.
TABLE-7: CORRELATION OF GESTATIONAL AGE
WITH TCD
GESTATIONAL AGE CORRELATIONCOEFFICIENT P value
20-22 WEEKS r = 0.862 <0.001
32-34 WEEKS r =0.803 <0.001
Significant correlation exists between Gestational Age and TCD.
TABLE-8 : CORRELATION OF GESTATIONAL AGE WITH AC
GESTATIONAL
AGE
CORRELATION
COEFFICIENT P value
20-22 WEEKS 0.688 <0.001
32-34 WEEKS 0.486 <0.001
Significant correlation exists between gestational age and AC.
TABLE-9 : CORRELATION BETWEEN TCD AND AC
AT 20-22 WEEKS
TCD AC
Pearson Correlation 1 .790(**)
Sig. (2-tailed) . .000TCD
N 90 90
Pearson Correlation .790(**) 1
Sig. (2-tailed) .000 .AC
N 90 90
**  Correlation is significant at the 0.01 level (2-tailed).
TABLE-9 : CORRELATION BETWEEN TCD AND AC
AT 32-34 WEEKS
TCD AC
Pearson Correlation 1 .569(**)
Sig. (2-tailed) . .000TCD
N 90 90
Pearson Correlation .569(**) 1
Sig. (2-tailed) .000 .AC
N 90 90
**  Correlation is significant at the 0.01 level (2-tailed).
TABLE -10 : CORRELATION OF TCD & AC  WITH
IN UTERO GROWTH STATUS  AT  32-34 WEEKS
In utero Growth Status
FGR AGA
Study
parameters
Mean SD Mean SD
P value
TCD 3.96 0.18 4.03 0.15 0.183
AC 24.1 1.18 27.87 1.48 <0.001
There was no statistically significant difference between the mean
TCD of  FGR & AGA whereas there was statistically significant
difference between the mean AC of FGR and AGA fetuses.
TABLE-11 : COMPARISON OF TCD/AC RATIO AT 20- 22
WEEKS AND  32-34 WEEKS IN AGA FETUSES
GA TCD/AC RATIO p VALUE
20-22 weeks 14.29±0.73(SD)
32-34 weeks 14.49±0.62(SD)
>0.073
There was no statistically  significant difference between the
TCD/AC ratio at 20-22 weeks and 32-34weeks.
TABLE-12: DISTRIBUTION OF FGR/AGA FETUSES WITH
RESPECT TO CUT-OFF VALUE OF TCD/AC RATIO
AT 32-34 WEEKS
TCD/ AC Ratio
14.49+ 2SD
(1.24)
FGR AGA TOTAL
≤ 15.73 2 89 91
> 15.73 8 1 9
Total 10 90 100
The cut-off value 15.73 diagnosed 8 cases of FGR and missed 2
cases of  FGR.
TABLE 13 : MEAN TCD/AC RATIO IN FGR AND AGA FETUSES
AT 32-34 WEEKS
In utero growth status TCD/AC
Ratio
     No of  babies p value
FGR 16.44 10
AGA 14.49 90 <0.001
There was statistically significant difference between the mean
TCD/AC ratio of FGR and AGA fetuses.
TABLE-14: DIAGNOSTIC VALUE OF TCD/AC RATIO IN FGR
Parameter Sensitivity Specificity PPV NPV
TCD/AC 80% 98.8% 88.8% 97.8%
Sensitivity and PPV of TCD/AC ratio in diagnosing FGR was 80%
and 88.8% respectively. Specificity and NPV in diagnosing FGR was
98.8% and 97.8% respectively.
TABLE-15: BIRTH WEIGHT PATTERN IN RELATION TO
IN-UTERO GROWTH STATUS
BIRTH WEIGHT IN KG P valueIN-UTERO
GROWTH STATUS Range Mean Mean + SD
FGR 1.5 – 2.25 2.22 2.22+0.28
AGA 2.25 – 3.7 2.99 2.99+0.24
<0.001
Mean birth weight of babies with FGR is 2.22 kg. Mean birth
weight of babies with AGA is 2.99 kg. There is statistically significant
difference between the mean birthweight of both groups.
Birth weight
TCD/AC at 20-22 weeks Pearson Correlation -.417(**)
Sig. (2-tailed) .000
N 90
TCD/AC at 32-34 weeks Pearson Correlation -.544(**)
Sig. (2-tailed) .000
N 90
*  Correlation is significant at the 0.05 level (2-tailed).
**  Correlation is significant at the 0.01 level (2-tailed).
2.22+0.28 2.99+0.24
TABLE-16 : APGAR SCORE
SCORE < 7 SCORE ≥ 7
AGA FGR AGA FGRAPGARSCORE
No. % No. % No. % No. %
At 1 Minute 13 14.4% 9 90% 77 85.6% 1 10%
At 5 Minutes 1 1.1 3 30% 89 98.9% 7 70%
90% of FGR babies were scored 1 minute APGAR of  <7
compared to only 14.4% in  AGA.
TABLE-16 : NICU ADMISSION
AGA FGRNICU ADMISSION
IN DAYS Number Percentage Number Percentage
Nil 84 93.3% 1 10%
1-5 4 4.5% 6 60%
6-10 2 2.2% 2 20%
> 10 0 0% 1 10%
90% of FGR babies needed NICU admission whereas only 6.7% of
the AGA babies needed NICU admission.
TABLE-17 :  IN-UTERO GROWTH STATUS AND PERINATAL
MORTALITY
PERINATAL MORTALITYIN-UTERO GROWTH STATUS
Number Percentage
AGA 0 0%
FGR 2 20%
The perinatal mortality was  20%  among FGR babies whereas it
was 0% among AGA babies.
TABLE-18 :  PERINATAL MORBIDITY
AGA FGRIN-UTERO GROWTH
STATUS
Number Percentage Number Percentage
Asphyxia 1 1.11% 1 10%
Meconium Aspiration
Syndrome 2 2.22% 2 20%
Hypoglycemia 2 2.22% 3 30%
Hypocalcemia 2 2.22% 2 20%
Hypothermia - 1 10%
Perinatal morbidity was high in FGR babies.
Discussion
DISCUSSION
In this study 100 antenatal women were selected after fulfilling the
inclusion and exclusion criteria.
In the present study 57% of the women were between  21 to 25
Years and most of the women were primigravida  accounted for 63%.
Risk factors associated with present pregnancy were preeclampsia
in 9%, chronic hypertension in 1%, oligohydramnios in 5% and GDM in
2%. Of which 55.6%  of preeclamptic and 80% of oligohydramnios
patients delivered FGR babies. Patients with chronic hypertension and
GDM also delivered FGR  babies.
In our study 94% of patients were delivered at term and 6% of
patients were delivered preterm. Out of 6 cases of preterm 33.3% were
delivered FGR babies with TCD within mean+2SD of normal
pregnancies.
In our study 69 women were delivered vaginally and 31 were
delivered by LSCS. Among FGR 50% were delivered by LSCS,
indications were fetal distress and oligohydramnios.
In the present study out of 100 pregnant women 10% were
delivered  FGR babies (birth weight <10th percentile), which is similar to
general incidence of 3-10% [1].
In our study a strong correlation was noted between gestational age
determined by last menstrual period and fetal TCD between 20-22
weeks(r = 0.876) and 32-34 weeks(r = 0.803) (p<0.001), similar to
correlation of TCD and gestational age (r = 0.955) in the study conducted
by Haller et al [78]. In the study conducted by Dilmen et al[76] the pearson
correlation r =0.9767, which is also close to our study.
In our study a significant correlation exists between the gestational
age determined by the last menstrual period and AC at 20-22 weeks (r =
0.688) and 32-34 weeks (r = 0.486) (p<0.001). In the study conducted by
Haller et al [78] there was strong correlation exists between gestational age
and AC (r = 0.9453) which is almost close to our study.
There was a significant linear correlation on noted between TCD
and AC at 20-22 weeks (r = 0.790) and 32-34 weeks (r = 0.588) (P<0.01)
in this study, similar to study conducted by Campbell et al [72] where
strong linear correlation (r =0.918) noted between TCD and AC.
In our study there is no statistically significant difference between
the mean TCD of FGR and AGA fetuses (p>0.05), Similar to study
conducted by Reece et al[70], in which the TCD was not affected in FGR.
In another study conducted by Vinkesteijn et al[76], the TCD was only
mildly affected even in severe FGR, this is also close to our study. The
concept that TCD is not affected even in FGR, is explained by the sparing
of blood flow to the cerebellum in IUGR as suggested by Berhman et al
(1970)[3].
This study shows a statistically significant difference between the
mean AC of FGR and AGA fetuses (p<0.001). This again proves that in
FGR the AC will be affected more as the liver size is reduced due to
reduced glycogen store[34].
In our study the TCD/AC ratio was 14.44±0.71 at 20-22 weeks
(TCD1/AC1 ratio) and 14.49±0.62 at 32-34 weeks (TCD2/AC2 ratio) for
normal pregnancies. There was no statistical difference between the two
values implying that TCD/AC ratio was fairly constant throughout
pregnancy, similar to study conducted by Meyer et al[69] , in which the
TCD/AC ratio remained constant throughout pregnancy with respect to
gestational age. In another study conducted by Campbell et al[72] ,the ratio
calculated after each examination and the ratio remained constant which
is also similar to our study.
In this study the mean +2SD of the TCD/AC ratio at 32-34 weeks
is taken as cut-off value for diagnosing FGR. Here, the TCD/AC ratio is
14.49+0.62 comparable with study of Malik et al[68] in which the
TCD/AC ratio was 14.06+0.59.
The  cut-off value of TCD/AC ratio 15.73 in our study is close to
the study conducted by meyer et al (1994)[69] in which the cut-off value
for fetal growth restriction was15.9 ,and also with the study of  haller et al
[77]. In another study conducted by Tongsong et al(1999)[75]  the cut-off
value is 15.4 which is also close to our study.
In our study   the sensitivity, specificity, PPV and NPV of
TCD/AC ratio in diagnosing FGR were 80%, 98.8%, 88.8% and 97.8%
respectively. Which is comparable with the study of Meyer et al(1994)[69]
in which the sensitivity, specificity, PPV and NPV were 83.9%, 96.8%,
94.5% and 88.2% respectively.
In our study out of 10 cases of FGR 9 were  asymmetrical and one
symmetrical .out of 9 cases of asymmetric FGR 7 were diagnosed by the
cut-off value of TCD/AC ratio with the sensitivity of 77.7%, similar to
study of Meyer et al[69] where the sensitivity is 83.9%.
In our study one were symmetrical FGR which was diagnosed by
the TCD/AC ratio with the sensitivity of 100%. In the study conducted by
Meyer et al (1994)[69], TCD/AC ratio diagnosed symmetric FGR with a
sensitivity of 71%. In our study the higher sensitivity is probably because
of small sample size.
In our study  one was  found to be severe FGR which had TCD/AC
ratio within cut-off value, and this is due to the fact that cerebellum
mildly affected in severe FGR, similar to  study by vinkesteijn et al[76].
In our study, significant negative correlation exists between the
TCD/AC ratio and the birth weight.
      Perinatal morbidity was high in FGR babies compared to AGA
babies. Perinatal mortality was 20% in FGR babies.
Summary
SUMMARY
Hundred antenatal women with excellent dates attending  antenatal
clinic were selected in the department of obstetrics and gynaecology,
R.S.R.M., Lying In hospital, Stanley medical college, Chennai.
Observations in the study includes
 Antenatal women  in the study group were in 18-34 years with
majority of the study population in the age group of 21-25 years.
 63% of the patients in the study were primigravida and 37% were
multigravida.
 Risk factors found in cases of fetal growth restriction were
preeclampsia 50%, oligohydramnios 40%, and chronic
hypertension in 10%.
 Ultrasonography was done twice between 20-22 weeks and 32-34
weeks and the TCD, AC measured and TCD/AC ratio calculated.
 Antenatal women were followed till delivery and the babies were
examined by the neonatologist .Babies were grouped in to
appropriate for gestational age(AGA), FGR according to birth
weight percentile.
 In 100 antenatal women, 10 were delivered  FGR babies.
 The ultrasonographic measurements TCD, AC and TCD/AC ratio
were analyzed separately in both groups(women  delivered
AGA(90) or FGR(10) ).
 Correlation were analyzed between gestational age and TCD,
gestational age and AC and between TCD and AC. Strong
correlation existed between these parameters in pregnancies with
AGA fetuses.
 In pregnancies with FGR strong correlation existed between
gestational age and TCD.  Correlation were not significant between
gestational age and AC, and TCD and AC as the reduced in FGR.
 The cut-off value of TCD/AC ratio for diagnosing FGR was
arrived from mean+2SD of AGA fetuses at 32-34 weeks. The cut-
off value in our study was 14.49+0.62.
 The 5th and 95th percentile of TCD/AC ratio in this study is 13.25-
15.73 and the mean is 14.49+0.62(2SD) .
 The TCD/AC ratio was fairly constant throughout  pregnancy.
 TCD/AC ratio diagnosed 8 out of 10 cases of FGR. The sensitivity,
specificity, PPV and NPV 80%, 97.8%, 88.8% and98.8%
respectively.
 TCD/AC ratio is a method used for assessment of fetal growth as it
is independent of GA. There was a significant difference in the
TCD/AC ratio of fetuses with or without FGR, thus providing a
standard means of establishing growth parity.
Conclusion
CONCLUSION
1. The TCD and AC measurements correlates well with
gestational age.
2. The TCD and AC has strong linear relationship, hence the
TCD/AC ratio is fairly constant throughout pregnancy.
3. TCD unlike AC is not affected in FGR, because of brain
sparing.
4. Hence, TCD/AC ratio is increased in FGR.
5. As the TCD/AC ratio is constant throughout the pregnancy, it is
a gestational age independent parameter, can diagnose FGR in
antenatal women with unknown gestational age.
6. Hence, TCD/AC ratio can be a screening test to diagnose FGR
in the antenatal period. So, that early intervention could be
attempted to improve the perinatal outcome.
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Annexures
Proforma
PROFORMA
Name
Age
Menstrual History
Obstetric Code
LMP
EDD
Dating Ultrasonogram :     done  / not done
Risk Factors
Preeclampsia Yes / No
Chronic Hypertension Yes / No
Oligohydramnios Yes / No
Gestational Diabetes Mellitus Yes / No
Chronic Renal Disease Yes / No
Vasculopathy Yes/No
Others Yes / No
GENERAL PHYSICAL EXAMINATION
Built & nourishment
Pallor / Icterus   / Cyanosis / Clubbing /  Lymphadenopathy / Edema
VITAL SIGNS : T: PR: RR: BP:
Breast :
Thyroid :
Spine :
HT : WT :
SYSTEMIC EXAMINATION
CVS :
RS :
CNS :
OBSTETRIC EXAMINATION
Date WT BP
P/A SFH P/V
INVESTIGATIONS
Routine:
Hb% HIV BT
PCV Hbs Ag CT
Urine Routine VDRL
Blood Group and RH Typing FBS PPBS
Blood Urea Serum Creatinine Electrolytes
Serum Uric acid  Serum fibrinogen
LFT:
Total bilirubin: ALT: AST:
SAP: Total protein Albumin:
Urine:
Albumin Sugar: Deposits
SAP: Total protein: Albumin:
24 hours urinary protein:
Cardiotocography:
Ultrasonogram :
I Trimester USG:
CRL:
GSac
GA
FH
USG at 20-22 weeks
BPD
HC
FL
AC
TCD
FH
Liquor
TCD/AC
Anomaly Yes / No :
USG at 32-34 weeks
BPD
HC
FL
AC
TCD
FH
Liquor
TCD/AC
Gestational Age at Delivery :
Mode of Delivery: Vaginal / LSCS :
New born Details
Birth weight :
In-utero growth status :
APGAR at one minute :
APGAR at 5 minutes :
NICU Admission :
Perinatal Morbidity :
Perinatal Mortality :
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1 kala 26 primi 21 2.1 16.4 33.1 4 30.6 12.8 13.07 39 3.5 AGA 7 8 1
2 nadhiya 24 primi 21.3 2.3 16.1 32.2 3.8 26.2 14.29 14.5 38 2.9 AGA 7 8 1
3 viji 20 primi 21.5 2.4 18 33 4 29.2 13.33 13.7 39 3 3.3 AGA 7 8 2
4 ameena 22 G2a1 20.2 1.9 13.6 32.2 3.8 27.5 14 13.82 39 2.9 AGA 7 8 1 1
5 faritha 19 G2P1L1 21 2.3 15.1 33.2 4.2 27 15.23 15.55 37 1,2 2.25 FGR 3 4 7 1 1 2
6 amudha 22 primi 21.1 2.3 16.4 32.3 3.9 27.2 14.02 14.34 38 2.7 AGA 7 8 1
7 kanmani 24 primi 21.4 2.4 19.2 32.2 3.9 30.2 12.5 12.91 39 3.6 AGA 7 8 2
8 sudha 29 G3A2 21.3 2.3 15.3 33 3.8 25.2 15.03 15.08 39 2.8 AGA 7 8 1
9 dhivya 22 primi 22.2 2.5 18.4 34.2 4.2 30.7 13.59 13.68 38 3.3 AGA 7 8 2
10 shakila 18 primi 21.2 2.2 14.3 33.5 4.1 27 15.38 15.19 39 3.3 AGA 7 8 2 2
11 kamatchi 27 primi 20.1 2 15.2 32.4 3.9 28.1 13.16 13.88 39 3.2 AGA 7 8 1
12 uma 21 primi 21.2 2.3 15 32.3 3.8 24.8 15.33 15.32 37 2.6 AGA 7 8 1 2
13 nandhini 26 G2P1L1 21.1 2.2 15.3 33.1 4 27.2 14.38 14.71 38 2.75 AGA 6 8 1
14 bharathy 28 primi 20.2 1.9 13.8 32.6 3.9 23.3 13.77 16.74 37 1,2 1.9 FGR 15 4 6 2 1 3
15 priya 31 G3P1L1A1 21 2.1 16.4 32.2 3.9 30.6 12.8 12.75 39 3.7 AGA 7 8 1
S.N
o
na
me
ag
e
Ob
ste
tric
 Co
de
GA
1
TC
D1
AC
1
GA
2
TC
D2
AC
2
TC
D1
/A
C1
  R
ati
o (
%)
TC
D2
/A
C2
 Ra
tio
 (%
)
GA
 at
 De
liv
ery
Ris
k F
act
ors
BW
 in
 kg
In 
ute
ro 
gro
wt
h
sta
tus
NIC
U A
dm
iss
ion
 AP
GA
R 1
 AP
GA
R 5
Mo
de
 of
 De
live
ry
Ty
pe
 of
 FG
R
Pe
rin
ata
l M
orb
idi
ty
Pe
rin
ata
l M
ort
ali
ty
16 akila 20 primi 20.3 1.9 13.9 32.2 3.8 28 13.67 13.57 40 3.5 AGA 7 8 2
17 vani 28 G2P1L1 21 2.1 14.6 33.3 4.2 28.5 14.38 14.74 36 2.6 AGA 7 8 1
18 prema 22 primi 21.3 2.3 15.7 33.2 4.3 29.3 14.65 14.68 39 2.85 AGA 7 8 1
19 nagamani 32 G2P1L1 21.1 2.2 15.3 32.3 3.6 23.5 14.38 15.32 37 4 1.5 FGR 10 7 8 1 1 1 1
20 parvathy 26 G2P1L1 21.4 2.3 16 33 4 27.3 14.38 14.65 38 2.8 AGA 7 8 1
21 suryadevi 28 G3P2L1 20.5 2.1 14.3 32.2 3.9 23.5 14.69 16.6 38 2.2 FGR 2 5 7 1 1
22 menaka 21 primi 21.5 2.4 16.9 34.1 4.3 29.6 14.2 14.53 39 2.95 AGA 7 8 2
23 poongodi 28 G2A1 20.5 2.1 14 32.2 3.9 27 14.19 14.44 39 3.1 AGA 7 8 2
24 chitra 24 G2P1L1 22 2.3 17 33.3 4 26.9 14.71 14.87 37 2.8 AGA 7 8 1
25 abitha 26 primi 21.2 2.1 14.5 32.4 3.8 26.4 14.48 14.39 39 3.2 AGA 6 8 2
26 ranjana 21 primi 22 2.3 16.4 32.6 4 27.6 14.02 14.49 39 2.9 AGA 7 8 2
27 angel 23 primi 21.2 2.1 14.2 33.2 4.1 29 14.79 14.14 38 1 2.75 AGA 7 8 1
28 selvi 20 primi 21.1 2.3 17.9 33.4 4.1 30.8 12.84 13.31 39 3.4 AGA 7 4 6 1
29 raji 25 G2P1L1 22 2.3 16.3 32.6 3.9 28 14.11 13.93 39 3.1 AGA 7 8 1
30 preetha 24 primi 21 2.1 14.2 33.1 4 27 14.79 14.81 40 2.95 AGA 5 7 8 2
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31 kannagi 21 primi 21.4 2.4 16.1 33.4 4 26.4 14.91 15.15 39 2.85 AGA 7 8 1
32 revathi 31 primi 20.2 2.1 14.2 33.5 4.1 27.2 14.79 15.07 38 2.7 AGA 7 8 1
33 shobana 26 G2P1L1 21.4 2.4 15.6 33.2 4.1 26.6 15.38 15.41 35 2.25 AGA 3 6 7 1 4
34 janaki 23 G2A1 21.1 2.1 14.3 32 3.7 26.3 14.69 14.07 39 3 3.2 AGA 7 8 1
35 vahitha 25 G2P1L1 22.1 2.4 16.1 32.6 4 26.6 14.91 15.04 39 2.9 AGA 7 8 1
36 hema 21 primi 22 2.3 15.6 32.5 4.1 27.8 14.74 14.75 38 2.85 AGA 7 8 1
37 renuka 27 G3P1L1A1 21.5 2.3 15.5 33.3 4.3 28.8 14.84 14.93 39 2.85 AGA 4 5 7 2 3
38 vimala 23 primi 20.4 2.1 14.3 32.6 4 27.4 14.69 14.6 38 2.75 AGA 7 8 1
39 leena 26 primi 21.3 2.3 15.6 32.1 3.8 25.4 14.74 14.96 40 3 AGA 7 8 2
40 vani 23 primi 22.1 2.5 16 32.6 4 25.1 15.63 15.94 39 2.95 AGA 7 8 1
41 padma 23 primi 21.3 2.4 16.9 32.2 3.9 26.8 14.2 14.55 39 2.85 AGA 7 8 1
42 malar 21 primi 21.2 2.3 17.6 33 4.1 29.8 13.06 13.76 38 2.7 AGA 7 8 1
43 parveen 27 primi 20.4 2.1 14.1 33.2 4 27.2 14.89 14.71 39 2.95 AGA 6 7 2
44 roselin 25 G2P1L1 21 2.1 14.3 33.4 4.1 28.3 14.69 14.49 39 2.9 AGA 7 8 1
45 shanthi 29 G3P1L1A1 21.2 2.3 15.6 33.5 4.2 28.4 14.74 14.79 39 2.85 AGA 7 8 1
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46 manju 21 primi 20.5 2.1 14.9 33 4.1 28.6 14.09 14.34 38 2.75 AGA 6 8 1
47 maria 22 primi 22 2.5 16.9 32.6 4.2 28.3 14.79 14.84 39 2.95 AGA 7 8 1 4
48 anuradha 23 primi 21.5 2.3 15.3 33.1 4 23.5 15.03 17.02 38 2 1.95 FGR 2 4 7 1 1 3 1
49 lavanya 23 primi 21.4 2.4 16.2 32.4 3.9 26 14.81 15 39 3 AGA 6 7 1
50 razia 26 G2P1L1 22.4 2.6 17.9 32.5 3.9 26.2 14.52 14.89 35 2.3 AGA 6 7 8 1
51 sankari 27 G2a1 20 2.1 14.3 33 4 28.2 14.69 14.18 39 2.95 AGA 6 7 1
52 sinthiya 21 primi 21.5 2.4 16.3 33.1 4 26.4 14.72 15.15 38 1 2.8 AGA 7 8 1
53 jeeva 19 primi 21 2.2 15.3 32.4 3.9 26.6 14.38 14.66 39 3.1 AGA 7 8 2
54 laila 24 G2P1L1 20.5 2.2 14.6 32.3 3.9 26 15.07 15 39 3.25 AGA 7 8 1
55 sowmiya 24 G2P1L1 20 1.9 13.9 33 3.8 28 13.7 13.57 40 3.4 AGA 7 8 1
56 savitha 26 primi 21.3 2.3 17.1 32.6 4.1 29.3 13.45 13.99 38 2.75 AGA 7 8 1
57 chandra 21 primi 20 2 14 32.6 4 28.1 14.29 14.23 39 2.9 AGA 7 8 1
58 sultana 23 primi 20.1 2 14.1 33.6 4.3 29.6 14.18 14.53 38 2.75 AGA 7 8 2
59 shanthi 26 G2P1L1 21.1 2.3 15.7 33.5 4.2 28.6 14.65 14.69 39 2.95 AGA 7 8 1
60 sharmila 26 G3P1L1A1 21.2 2.2 15.2 33.5 4.2 25.4 14.47 16.54 38 1 2.25 FGR 3 5 7 1 1 3
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61 sandhiya 20 primi 22 2.4 16.3 32.4 3.9 26.5 14.72 14.72 40 3 AGA 7 8 1
62 vanitha 23 primi 21 2.1 14.3 33.1 4 27.2 14.69 14.71 38 2.9 AGA 7 8 1
63 kavitha 23 primi 22.2 2.5 15.9 33.2 4 26.2 15.72 15.27 38 2.9 AGA 7 8 2
64 suguna 28 G2P1L1 20.5 2.1 14 32 3.9 25.9 15 15.06 36 2.5 AGA 5 7 2
65 gomathi 21 primi 21.4 2.3 16 32.5 4.1 28.8 14.38 14.24 39 3 AGA 7 8 1
66 sundari 21 primi 21.3 2.3 16.1 32.3 4.1 29.5 14.29 13.9 39 2.9 AGA 7 8 2
67 devi 24 primi 22.3 2.5 19 32.5 4 29.4 13.16 13.6 38 3.3 AGA 7 8 2
68 sheela 27 G2P1L1 20 2.1 14.3 33 4.1 27.8 14.69 14.75 39 3 AGA 7 8 1
69 malathi 21 primi 21.1 2.3 16.5 33.6 4.3 30.1 13.94 14.29 37 2.7 AGA 7 8 1
70 surya 24 primi 21.2 2.2 14.2 34 4.3 28 15.49 15.36 40 3.1 AGA 7 8 2
71 vaishnavi 23 primi 21 2.3 16 32.6 4 27.6 14.38 14.49 38 2.9 AGA 4 8 1
72 pavithra 25 G2P1L1 20.6 2.1 14.1 32.2 3.9 26.4 14.89 14.77 38 3 AGA 7 8 1
73 girija 23 primi 20 20 16.2 33.3 4.1 30.6 12.35 13.4 39 3 AGA 7 8 1
74 geetha 23 primi 22.1 2.3 14.7 32.6 4 26.1 15.65 15.33 38 2.75 AGA 7 8 1
75 dhanam 23 primi 21.5 2.3 16.1 33 4 23.4 14.29 17.09 39 1 1.8 FGR 10 4 6 2 1 2
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76 mohana 21 primi 21.4 2.1 14.1 34 4.2 28.1 14.89 14.95 39 2.9 AGA 7 8 1
77 prabha 25 G2P1L1 22 2.3 15 33.4 4.2 27.6 15.33 15.22 39 2.95 AGA 7 8 1
78 roksana 20 primi 21.3 2.4 16.3 32 3.9 23.8 14.72 16.39 38 2 2.2 FGR 7 8 2 1 4
79 sivagami 29 G2P1L1 20.1 1.9 13.8 32.5 4 29.2 13.77 13.7 39 3.7 AGA 6 8 1
80 indra 30 G3P2L2 20.1 1.9 14.7 33 3.8 29.3 12.92 13.29 39 3.1 AGA 7 8 1
81 kumutha 23 primi 20.4 2.1 14.2 32.6 3.9 27.2 14.79 14.34 37 3 AGA 7 8 1
82 soniya 25 G2P1L1 20 2 14.1 34 4.2 30 14.18 14 39 3.4 AGA 2 7 8 1 3
83 gowri 23 primi 20.2 2 14 34.1 4.3 29.7 14.29 14.49 39 3.2 AGA 7 8 1
84 mala 21 primi 20.1 1.9 13.6 32.5 3.9 28.7 13.97 13.59 40 3.5 AGA 7 8 2
85 rachel 22 G2P1L1 22 2.3 15.9 33.4 4.1 23.7 14.5 17.29 37 1 1.75 FGR 4 6 7 2 1 4
86 sridevi 30 G3P2L2 21.5 2.4 16.3 33.1 4 27 14.72 14.81 38 3.2 AGA 7 8 1
87 megala 21 primi 22 2.5 18.8 32.6 4 26.6 15.29 15.04 38 3.1 AGA 7 8 2
88 usha 26 G2P1L1 20 2 14 33.5 4.1 28.5 14.29 14.39 39 3.4 AGA 7 8 1
89 dhanam 32 primi 21.6 2.5 16 34 4.3 27.8 15.63 15.47 39 1 3.2 AGA 7 8 1
90 pushpa 24 primi 20 1.9 13.8 33.6 4.2 30.5 13.77 13.77 39 2.9 AGA 7 8 1
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91 vasanthi 26 G3P1L1A1 21.3 2.4 16.2 32.3 3.9 26.9 14.81 14.5 40 3 AGA 7 8 1
92 rani 24 primi 21.4 2.3 15.1 32.4 3.9 26 15.23 15 39 2.9 AGA 7 8 2
93 bhuvana 20 primi 20.1 2.1 14 33.3 4.1 27.9 15 14.7 39 2.95 AGA 7 8 1
94 mangai 29 primi 20.4 2.2 13.4 32.3 3.8 23.9 16.42 15.9 36 2 1.8 FGR 3 5 7 2 2 5
95 rajathi 20 primi 21 2.3 15.5 34.3 4.3 29.2 14.84 14.73 39 2.95 AGA 7 8 1
96 eswari 24 primi 20.3 2.1 14.5 32 3.9 26.7 14.48 14.61 39 3 AGA 7 8 1
97 ramya 23 G2P1L1 22 2.5 16.5 32.4 4 26.6 15.15 15.04 40 3.1 AGA 7 8 2
98 anitha 27 G2P1L1 21 2.1 14 32.5 4 26.8 15 14.93 39 1 3.2 AGA 7 8 2
99 mohana 22 primi 20 2 14 34.2 4.2 29.4 14.29 14.29 39 3 AGA 7 8 1
100 rihana 23 primi 21.5 2.3 15.9 34.2 4.3 30.4 14.5 14.14 39 2.8 AGA 7 8 1
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 to
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KEY TO MASTER CHART
1 Obstetric Code
G Gravida
P Para
L Live
A Abortion
2 GA Gestational Age
1 20-22 weeks
2 32-34 weeks
3 TCD Transverse Cerebellar Diameter(in cm)
1 20-22 weeks
2 32-34 weeks
4 AC Abdominal Circumference (in cm)
1 20-22 weeks
2 32-34 weeks
5 TCD1/AC1Ratio (%) TCD/AC Ratio (%)  at 20-22 weeks
TCD2/AC2
Ratio (%) TCD/AC Ratio (%) at 32-34 weeks
6 Risk Factors
1 Preeclampsia
2 Oligohydramnios
3 GDM
4 Chronic Hypertension
7 BW Birthweight
8 In utero
growth Status
AGA Appropriate for Gestational Age
FGR Fetal Growth Restriction
9 NICUAdmission
Neonatal Intensive Care Unit
Admission
10 APGAR
1 1 minute
5 5 minutes
11 Mode ofDelivery
1 Vaginal
2 LSCS
12 Type of FGR
1 Asymmetrical
2 Symmetrical
13 PerinatalMorbidity
1 Asphyxia
2 Meconium Aspiration Syndrome
3 Hypoglycemia
4 Hypocalcemia
5 Hypothermia
